Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribonuclease pancreatic (RNase 1) is a secretory endoribonuclease enzyme encoded by the human RNASE1 gene. It is a member of the ribonuclease A superfamily and catalyzes the cleavage of RNA on the 3' side of pyrimidine nucleotides, with a preference for poly(C) substrates. Unlike related digestive homologs, human RNase 1 is widely expressed in many tissues and is found at remarkable concentrations in the blood and other biological fluids. It degrades both single- and double-stranded RNA and plays roles beyond digestion, particularly in regulating extracellular RNA in processes such as blood coagulation, inflammation, and innate immunity. The protein is monomeric, may be glycosylated at specific sites, and interacts with cell-surface glycans. Engineered forms of RNase 1 are being developed as anticancer agents. Abnormal serum levels or glycoforms of RNase 1 have been implicated as candidate biomarkers in certain cancers[1][2][3][5].
RNA degradation by endonucleolytic cleavage; Potential antitumor effect via targeted RNA hydrolysis in cancer cells
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribonuclease pancreatic (RNase 1).